Let's look at what we know, which is pretty simple. We know DM has told investors that a second licensing/partnerhsip deal will be announced "this year"....and of course this year only has 6 or so weeks left in it.

So the question is.....With whom? I'm assuming it will be for Apabetalone, but I could be wrong on that score. Apabetalone is not a form of insulin, like the drug you talked about in your link.

Their drug is a form of insulin meant for mealtimes from what I read.....nothing to do with MACE, and Novo's material talks of partnerships to enhance all aspects of the lives of diabetics, not just insulin and blood sugar management.

Yeah....I'd still say 50/50. Out of all the companines involved in treating and researching diabetes why did Resverlogix chose to re-tweet Novo's video? Hopefully we'll find out in a day or two, then you can either say my 50/50 call was idiotic, or that it was just a coincidence.